Analysis and treatment options for thymic cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study focuses on thymic malignancies, which are the most common tumors found in the anterior mediastinum. It aims to create a patient registry to identify genetic alterations in thymic tumors, which could help in predicting responses to novel targeted therapies. By understanding these molecular changes, the study seeks to develop more effective treatment options for patients with thymic cancers. The research emphasizes the importance of individualized treatment approaches based on molecular diagnostics.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically proven diagnosis of thymic malignancies
* 18 years of age or older
* Ability to understand and the willingness to sign a written informed consent document

Where it's running

• Xiaomin Niu
  Shanghai, Shanghai Municipality, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using hypofractionated radiotherapy for thymic epithelial tumors

  This study is testing if a shorter, more intense type of radiation therapy can help people with thymic epithelial tumors after surgery feel better and have fewer side effects compared to the standard treatment.

  Recruiting Xiangya Hospital of Central South University · Changsha, Hunan · NCT06692062

• Using AI to improve diagnosis and recurrence prediction in thymic tumors

  This study is testing if artificial intelligence can help doctors better diagnose thymic tumors and predict the chances of them coming back for patients with these rare cancers.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT06301945

• Using PT-112 to treat thymoma and thymic carcinoma

  This study is testing a new treatment called PT-112 to see if it can help shrink tumors in patients with thymoma and thymic carcinoma who have already tried other chemotherapy.

  Recruiting Phase 2 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT05104736

• Postoperative Hypofractionated Radiotherapy for Stage II/III Thymic Epithelial Tumors

  This study tests whether giving a shorter course of higher-dose radiotherapy after complete tumor removal is safe for adults with Stage II/III thymic epithelial tumors.

  Recruiting Phase 2 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT07691619

• Target-Selected CAR-NK Cells for B2 Thymoma or Thymic Carcinoma

  This study tests whether CAR-NK cells targeting CD30, CD5, or mesothelin can be safely given to adults whose B2 thymoma or thymic carcinoma has come back or not responded to treatment.

  Recruiting Phase 1/2 Beijing Biotech · Shenzhen, Guangdong · NCT07598955

• Sacituzumab Tirumotecan for locally advanced or metastatic thymic carcinoma

  This trial tests whether Sac-TMT can help people with thymic carcinoma after one prior platinum-based therapy.

  Recruiting Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Shanghai · NCT07324629

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.